ChemoCentryx (CCXI) Tops Q3 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
ChemoCentryx Reports Third Quarter 2021 Financial Results and Recent Highlights
November 9, 2021 4:05 PM EST-- U.S. Food & Drug Administration (FDA) approves TAVNEOSTM (avacopan) in ANCA-Associated Vasculitis in October --
-- TAVNEOS now launched in the U.S. --
-- TAVNEOS approved also in Japan; European CHMP opinion expected this month --
-- Pipeline advances: Company intends to meet with FDA on path for TAVNEOS in C3 Glomerulopathy (C3G) and Hidradenitis Suppurativa (HS); plans to initiate clinical development of TAVNEOS in Lupus Nephritis (LN) in 2022 --
-- Clinical development underway of next... More
